Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct

Description

This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions and are treated with either current accepted management, or accepted management in addition to transcutaneous auricular vagal nerve stimulation.

Conditions

Acute Ischemic Stroke

Study Overview

Study Details

Study overview

This is a randomized open-label, with blinded outcome pilot study to evaluate the effect on inflammatory laboratory values and explore clinical outcomes in patients who present with ischemic strokes due to large vessel occlusions and are treated with either current accepted management, or accepted management in addition to transcutaneous auricular vagal nerve stimulation.

Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct

Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct

Condition
Acute Ischemic Stroke
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University in St. Louis School of Medicine, Saint Louis, Missouri, United States, 63110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult patients who present with acute ischemic strokes due to large vessel occlusions
  • * \<18 years old
  • * patients with presumed chronic large vessel occlusions
  • * NIHSS\<6
  • * pre-morbid modified Rankin score (mRS) \>2
  • * unable to initiate treatment under 36 hours from symptom discovery
  • * Chronic or severe infection
  • * life expectancy \<3 months
  • * patients' undergoing active cancer or immunosuppressive/modulating therapy
  • * patients with sustained bradycardia on arrival with a heart rate \<50 beats per minute.

Ages Eligible for Study

18 Years to 99 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Washington University School of Medicine,

Study Record Dates

2024-12-23